Clinical Trial Update: Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure [Phase 2]

View source ↗

Summary

Phase 2 trial investigating potassium reduction with Sodium Zirconium Cyclosilicate (SZC) to optimize RAAS inhibition in heart failure; study terminated with po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Sodium Zirconium Cyclosilicate (sodium zirconium cyclosilate)

Snippet

Sponsor: AstraZeneca | Conditions: Heart Failure | Phase 2 | Status: TERMINATED | Results posted: 2021-06-15